Lundbeck backs Trintellix with new data

New clinical data from a trial involving Lundbeck's Trintellix in patients with depression and anxiety will put wind in the drug's sails.

Photo: Jens Dresling

A particular group of patients have proven to benefit from being treated with Lundbeck's Trintellix/Brintellix – a group which has otherwise had difficulty finding treatment, according to a Lundbeck press release.

The study contained 100 patients with a primary diagnosis of major depressive disorder (MDD) and a comorbid diagnosis of generalized anxiety disorder (GAD).

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs